저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:

저작자표시. 귀하는 원저작자를 표시하여야 합니다.

비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.

변경금지. 귀하는 이 저작물을 개작, 변경 또는 가공할 수 없습니다.

귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내야 합니다.
저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다.

Disclaimer
A hierarchical prognostic model for risk stratification in patients with early breast cancer according to $^{18}$F-fluorodeoxyglucose uptake and clinicopathological parameters

Jong Tae Cha

Department of Medicine

The Graduate School, Yonsei University
A hierarchical prognostic model for risk stratification in patients with early breast cancer according to $^{18}$F-fluorodeoxyglucose uptake and clinicopathological parameters

Jong Tae Cha

Department of Medicine

The Graduate School, Yonsei University
A hierarchical prognostic model for risk stratification in patients with early breast cancer according to $^{18}$F-fluorodeoxyglucose uptake and clinicopathological parameters

Directed by Professor Mijin Yun

The Master's Thesis submitted to the Department of Medicine, the Graduate School of Yonsei University in partial fulfillment of the requirements for the degree of Master of Medical Science

Jong Tae Cha

December 2017
This certifies that the Master’s Thesis of Jong Tae Cha is approved.

------------------------------------
Thesis Supervisor: Young Up Cho

------------------------------------
Thesis Committee Member#1: Mijin Yun

------------------------------------
Thesis Committee Member#2: Min Jung Kim

The Graduate School

Yonsei University

December 2017
ACKNOWLEDGEMENTS

I was able to write this paper thanks to many people.

First of all, I give my sincere thanks to Professor Mijin Yun, who is my thesis director. She showed me how a true researcher should look like. She taught me not only the knowledge but also the wisdom to live my life so that I become a nuclear medicine doctor.

In addition, I am indebted to Professor Young Up Cho and Professor Min Jung Kim who gave me sharp introductions and warm advice for this paper.

I also give my thanks to the Professors of the department of nuclear medicine who taught and encouraged me a lot.

Especially, I would likely to give my thanks to my father and mother who trusted me continuously all the time.

Jong Tae Cha
<TABLE OF CONTENTS>

ABSTRACT  ........................................................................................................... 1

I. INTRODUCTION .................................................................................................. 3

II. MATERIALS AND METHODS ............................................................................ 4

   1. Patient ............................................................................................................. 4
   2. PET/CT imaging ............................................................................................. 5
   3. Measurement of PET Parameters ................................................................. 6
   4. Histological Evaluation and Categorization of Molecular Subtypes .......... 6
   5. Statistical Analysis ....................................................................................... 7

III. RESULTS .......................................................................................................... 8

   1. Patient Characteristics .............................................................................. 8
   2. Clinicopathological and Imaging Prognostic Factors for RFS ............... 10
   3. Risk Stratification Using CART Analysis ................................................ 12
   4. Kaplan-Meier Survival Analysis in 4 Risk Layers on CART Modeling ... 12

IV. DISCUSSION ...................................................................................................... 14

V. CONCLUSION .................................................................................................... 16

REFERENCES ......................................................................................................... 17

ABSTRACT(IN KOREAN) ....................................................................................... 21
LIST OF FIGURES

Figure 1. Classification and regression tree analyses to identify synergistic/antagonistic associations between prognostic factors··13

LIST OF TABLES

Table 1. Patient Characteristics……………………………………………………9

Table 2. Univariate and Multivariate Analysis of Recurrence free Survival…………………………………………………………11
ABSTRACT

A hierarchical prognostic model for risk stratification in patients with early breast cancer according to $^{18}$F-fluorodeoxyglucose uptake and clinicopathological parameters

Jong Tae Cha

Department of Medicine
The Graduate School, Yonsei University

(Directed by Professor Mijin Yun)

**Purpose:** The purpose of this study was to investigate the prognostic value of $^{18}$F-fludeoxyglucose (FDG) uptake in the primary tumor on positron emission tomography/computed tomography (PET/CT) for recurrence-free survival (RFS), as well as interactions between clinicopathological and metabolic prognostic factors for risk stratification in patients with early stage breast cancer who underwent surgery without neoadjuvant chemotherapy.

**Methods:** Between January 2008 and December 2013, 524 patients with early stage breast cancer who had undergone $^{18}$F-FDG PET/CT for initial staging and surgery without neoadjuvant treatment were included. The Cox proportional hazards model for RFS was used with clinicopathological variables and maximum standardized uptake value (SUVmax) on PET/CT. After classification and regression tree (CART)
modeling, RFS curves were estimated using the Kaplan-Meier method and differences in each risk layer were assessed using the log rank test.

**Results:** During a median follow-up duration of 46.2 months, 31 (5.9%) patients experienced recurrence (8 loco-regional recurrence, 23 distant metastases). In univariate analysis, SUVmax (>6.75), tumor size (>2.0 cm), and triple negative (TN) subtype were significant for RFS. In multivariate analysis, SUVmax was the only independent prognostic factor for RFS (p=0.028). The CART model identified 4 risk layers: group 1 (SUVmax ≤6.75 and tumor size ≤2.0 cm); group 2 (SUVmax ≤6.75, tumor size >2 cm, and Luminal A [LumA] or TN); group 3 (SUVmax ≤6.75, tumor size >2.0 cm, and Luminal B [LumB] or human epidermal growth factor receptor 2 [HER2]-enriched); group 4 (SUVmax >6.75). Five-year RFS was as follows: 95.9% (group 1), 98% (group 2), 82.8% (group 3), and 85.4% (group 4). Group 3 or 4 showed worse prognosis than group 1 or 2 (group 1 vs. group 3: p=0.040 after adjustment; group 1 vs. group 4: p<0.001 after adjustment; group 2 vs. group 3: p=0.016 after adjustment; group 2 vs. group 4: p<0.001 after adjustment).

**Conclusion:** High SUVmax (>6.75) in primary breast cancer was an independent prognostic factor for poor RFS. In patients with low SUVmax, LumB or HER2-enriched subtype tumor >2 cm was also a prognostic factor for poor RFS, similar to high SUVmax.

---

Key words: early breast cancer, risk model, ¹⁸F-FDG PET/CT, recurrence free survival
A hierarchical prognostic model for risk stratification in patients with early breast cancer according to $^{18}$F-fluorodeoxyglucose uptake and clinicopathological parameters

Jong Tae Cha

Department of Medicine

The Graduate School, Yonsei University

(Directed by Professor Mijin Yun)

I. INTRODUCTION

Breast cancer is the most common malignancy among women worldwide.\textsuperscript{1} Due to increased screening, the majority of patients present with early stage disease.\textsuperscript{2} Treatment of choice in early breast cancer (stage 0, I, and, II) is surgical resection followed by adjuvant chemotherapy according to clinicopathological risk factors.\textsuperscript{3, 4} The known prognostic factors are axillary nodal status, tumor size, tumor pathology, tumor grade, peritumoral lymphatic vessel and vascular invasion, hormonal receptors, proliferation markers, ethnicity, and age, among others.\textsuperscript{5} In addition, five intrinsic subtypes based on gene expression profiles have shown distinct tumor phenotypes in predicting patient outcomes.\textsuperscript{6, 7} Genomic risk stratification has been also useful in selecting patients who would benefit from adjuvant chemotherapy.\textsuperscript{8} Due to limitations preventing the routine use of gene expression profiling, immunohistochemistry (IHC) staining for hormonal receptors and human epidermal growth factor receptor 2 (HER2) has been preferred as a therapy-oriented surrogate of intrinsic subtype.\textsuperscript{9, 10}
18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has advantages over conventional imaging modalities in that it offers non-invasive, semi-quantitative information about metabolically active tumor burden, tumor biology, and patient prognosis.11-13 Unlike pathological and genomic prognostic factors, clinically relevant information can be provided in preoperative settings with potential therapeutic implications. Although maximum standardized uptake value (SUVmax) in primary breast cancer has been found to be an independent prognostic factor for survival, studies have included patient populations with different risks for recurrence by including both early and locally advanced cancers, with or without neoadjuvant chemotherapy. Nevertheless, a risk stratification model using metabolic variables on PET/CT combined with other known prognostic factors has not been proposed.

The purpose of this study was to investigate the prognostic value of 18F-FDG uptake in the primary tumor for recurrence-free survival (RFS) in patients with early breast cancer who underwent surgery without neoadjuvant chemotherapy. In addition to conventional statistical modeling of prognosis, a hierarchical prognostic system was applied to identify further synergistic/antagonistic interactions between clinicopathological prognostic factors and 18F-FDG uptake.

II. MATERIALS AND METHODS

1. Patients

Data from patients with breast cancer who underwent 18F-FDG PET/CT at initial staging between January 2008 and December 2013 were retrieved from the institutional medical database. Patients were included if they had pathologically proven breast cancer and IHC results for estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 status. To be included, patients also had to have undergone mastectomy with sentinel lymph node dissection and/or axillary lymph node dissection without neoadjuvant treatment. Among these (n=672), patients with
locally advanced breast cancer (N2/3 classified according to 7th edition of American Joint Committee on Cancer [AJCC]) were excluded (n=19). Tumors <1 cm in size were excluded to minimize a partial-volume averaging effect affecting semi-quantitative measurement of $^{18}$F-FDG uptake (n=103). Patients who had bilateral breast cancers were excluded (n=11). Patients visited the hospital every 3 months for the first year of follow-up. Routine examinations, including breast sonography, and whole body bone scan, were performed every 6 months for the first year and annually thereafter. Mammography was performed annually. Whenever abnormal findings were noted, further diagnostic studies were performed for confirmation. Patients without regular follow-up data were excluded (n=15). Finally, 524 patients were included in the analysis. This study was approved by the Institutional Review Board of our Hospital. Given the retrospective nature of this study and the use of anonymized data, the requirement for informed consent was waived.

2. PET/CT Imaging

PET/CT was performed using a scanner (Discovery STE; GE Healthcare, Milwaukee, WI or Biograph TruePoint 40; Siemens Medical Systems, Knoxville, TN) with 16- or 40-slice CT, respectively. Patients fasted for at least 6 h before imaging, and glucose levels in the peripheral blood were ≤140 mg/dL before the injection of $^{18}$F-FDG. An $^{18}$F-FDG dose of approximately 5.5 MBq/kg was administered intravenously 1 h before image acquisition. After the initial low-dose CT study (Discovery STE, 30 mA, 130 kVp or Biograph TruePoint 40, 36 mA, 120 kVp), a standard PET protocol was used to scan from the neck to the proximal thighs with an acquisition time of 2.5 min per bed position in the three-dimensional mode. PET images were reconstructed using ordered subset expectation maximization with CT images for attenuation correction.

3. Measurement of PET Parameters
Two experienced nuclear medicine physicians reviewed all PET/CT images; discrepancies were resolved by consensus. Metabolic parameters were measured using Volume Viewer software (GE Healthcare, USA). For semi-quantitative analysis, a volume of interest was drawn for each lesion to measure SUVmax. SUVmax was calculated using the following formula: (decay-corrected activity [kBq]/tissue volume [mL])/(injected $^{18}$F-FDG activity [kBq]/body mass [g]).

4. Histological Evaluation and Categorization of Molecular Subtypes

All patients underwent surgical resection for breast cancer with sentinel lymph node biopsy and/or axillary lymph node dissection. Histological type, tumor size, tumor grade, and lymphovascular invasion (LVI) status were determined from the surgically excised specimens. Tumor, node, and metastasis (TNM) staging was performed according to the 7th edition of the AJCC. The histological grade of each tumor was determined using the modified Bloom-Richardson classification.

Formalin-fixed, paraffin-embedded tissue blocks were used for IHC; the expression status of ER, PR, HER2, and Ki-67 was determined by IHC staining of the surgical specimen. Primary antibodies against ER (Clone SP1; Neomarkers for Lab Vision, Fremont, USA), PR (Clone PgR 636; DAKO, Glostrup, Denmark), HER2 (Clone Polyclonal; DAKO, Glostrup, Denmark), Ki67 (Clone MIB-1; DAKO, Glostrup, Denmark) were used. ER positivity (+) and PR (+) was defined as the presence of ≥1% positively stained nuclei in 10 high-power fields. HER2 staining was analyzed according to the American Society of Clinical Oncology/College of American Pathologists guidelines. The intensity of HER2 staining was scored as 0, 1+, 2+, or 3+. Tumors with a 3+ score were considered to be HER2 (+), whereas those with a 0 or 1+ score were considered to be HER2 negative (−). Tumors with a 2+ score were subjected to fluorescence in situ hybridization analysis to determine HER2 status. For Ki-67, nuclear staining ≥14% was considered to be high-level expression. According to different combinations of ER, PR, HER2 and Ki-67, the patients were categorized
into four different molecular subtypes as follows: Luminal A (LumA): ER (+) and/or PR (+), HER2 (−), and Ki-67 low (<14 %); Luminal B (LumB): ER (+) and/or PR (+), HER2 (−), and Ki-67 high (≥14%) or ER (+) and/or PR (+), HER2 (+), and any Ki-67 index; HER2-enriched: ER (−), PR (−), but HER2 (+); and Triple negative (TN): ER (−), PR (−), and HER2 (−).

5. **Statistical Analysis**

RFS was defined as the time from the operation date to the date of cancer recurrence. The prognostic values of clinicopathological factors, including age, tumor size, nodal status, TNM stage, histologic type, histologic grade, LVI, molecular subtypes, proliferation index, treatment modalities, and SUVmax, were assessed using a Cox proportional hazards model for RFS. Hazard ratio (HR) with Wald 95% confidence intervals (CI) were provided for the model. All continuous variables were grouped into two categories according to the optimal cut-off values determined using receiver-operating characteristic (ROC) curve analysis. Multi-collinearity among independent variables was evaluated using Spearman rank correlation coefficient before multivariate analysis.

Next, to identify further synergistic/antagonistic interactions between prognostic factors, a classification and regression tree (CART) was generated for RFS. Left truncated and right censored (LTRC) CART is a prognostic system with a hierarchical structure based on recursive partitioning that builds a decision tree to find subgroups at higher risk for recurrence. Factors that were statistically significant in univariate analyses were included in the CART analysis. Each node on the decision trees included subgroups of a population with common characteristics influencing RFS. HRs of each groups elicited by CART model were assessed using Cox proportional hazard model. Finally, cumulative RFS curves of each risk layer were estimated using the Kaplan-Meier method, and the statistical differences among the risk layers were
compared using the log rank test with pairwise comparison to account for multiple comparison correction.

All statistical analyses were performed using SPSS version 23 (IBM Corporation, Armonk, NY, USA) for Windows (Microsoft Corporation, Redmond, WA, USA) and R 3.33.0 software (The R Foundation for Statistical Computing, Vienna, Austria) with necessary analytical packages such as LTRC trees, rpart and survival; p<0.05 was considered to be statistically significant.

III. RESULTS

1. Patient Characteristics

The clinicopathological characteristics of the 524 female patients (median age 50 years [range, 27–82 years]) are summarized in Table 1. There were 270/524 (51.5%) patients with TNM stage I and 254/524 (48.5%) with stage II cancer. Of the 125/524 (23.9%) patients with lymph node metastasis (N1), 23/524 (4.4%) had known N1 metastasis according to ultrasonography-guided biopsy before surgery, and 102/524 (19.5%) exhibited lymph node metastasis only by sentinel lymph node sampling. There were 225/524 (42.9%) patients with LumA, 155/524 (29.6%) with LumB, 42/524 (8.0%) with HER2-enriched, and 102/524 (19.5%) with TN subtypes. The mean SUVmax of the primary tumors was 5.51 ± 4.10.

During a median follow-up duration of 46.2 months (range, 5.4–95.2 months), 31/524 (5.9%) patients experienced recurrence (8 loco-regional recurrence, 23 distant metastasis). Fourteen of the 270 patients with stage I and 17 of the 254 patients with stage II cancer had recurrence. According to molecular subtype, there was recurrence in 8/225 (3.6%) with LumA, 10/155 (6.5%) with LumB, 4/42 (9.5%) with HER2-enriched, and 9/102 (8.8%) with TN.
# Table 1. Patient Characteristics

| Variable                                      | Median value (range) |
|-----------------------------------------------|----------------------|
| Age (y)\(^1\)                                 | 50 (27 - 82)         |
| SUVmax (g/ml)                                 | 5.51 ± 4.10          |
| Tumor size (cm)                               | 1.92 ± 0.79          |
| Nodal status (n)                              |                      |
| Negative                                      | 399 (76.1%)          |
| Positive                                      | 102 (19.5%)          |
| Sentinel LN positive                          | 102 (19.5%)          |
| Axillary LN positive                          | 23 (4.4%)            |
| TNM stage (n)                                 | 270 (51.5%)/254 (48.5%) |
| Histologic type (n)                           | 457 (87.2%)/16 (3.1%)/51 (9.7%) |
| Histologic grade (n)                          | 110 (21.0%)/240 (45.8%)/174 (33.2%) |
| Lymphovascular invasion (n)                   | 465 (88.7%)/59 (11.3%) |
| Ki67 (%)                                      | 21.78 ± 21.70        |
| Molecular subtype (n)                         | 225 (42.9%)/155 (29.6%)/42 (8.0%)/102 (19.5%) |
| Adjuvant chemotherapy (n)                     | 430 (82.1%)/94 (17.9%) |

\(^1\)Median value (range)

\(^2\)Other: primary breast cancer other than Invasive Ductal Carcinoma (IDC) or Invasive Lobular Carcinoma (ILC).

Data are reported as mean with standard deviation unless otherwise specified.
2. Clinicopathological and Imaging Prognostic Factors for RFS

Optimal cut-off values for SUVmax and size were >6.75 and >2.0 cm, respectively. In univariate analysis, SUVmax (>6.75), size (>2.0 cm), and TN subtype were significant prognostic factors for RFS. In multivariate analysis, SUVmax was the only independent prognostic factor for RFS (HR 2.6 [CI, 1.1-6.1]; p=0.028) (Table 2).
| Variable                        | Univariate analysis | Multivariate analysis |
|--------------------------------|---------------------|-----------------------|
|                                | P-value             | Hazard ratio (95% CI) |
|                                |                     |                       |
| Age (≤35 vs. >35 y)            | 0.699               | 0.75 (0.17-3.16)      |
| SUVmax (≤6.75 vs. >6.75)       | 0.001               | 3.50 (1.69-7.23)      | 0.028 | 2.60 (1.10-6.14) |
| Tumor size (≤2cm vs. >2cm)     | 0.019               | 2.33 (1.15-4.74)      | 0.205 | 1.63 (0.76-3.46) |
| Nodal status (Negative vs. Positive) | 0.750             | 0.74 (0.30-1.82)      |
| TNM Stage (I vs. II)           | 0.544               | 1.24 (0.61-2.52)      |
| Histologic type                |                     |                       |
| IDC                            |                     |                       |
| ILC                            | 0.97                | 0.00                  |
| Other¹                         | 0.52                | 1.40 (0.49-4.02)      |
| Histologic grade (1 or 2 vs. 3)| 0.327               | 1.42 (0.70-2.91)      |
| LVI (Negative vs. Positive)    | 0.830               | 1.13 (0.39-3.24)      |
| Ki67 (≤14% vs. >14%)           | 0.054               | 2.09 (0.98-4.45)      |
| Molecular subtype              |                     |                       |
| LumA                           |                     |                       |
| LumB                           | 0.183               | 1.18 (0.74-4.76)      | 0.658 | 1.24 (0.46-3.33) |
| HER2-enriched                  | 0.108               | 2.67 (0.80-8.91)      | 0.529 | 1.51 (0.41-5.49) |
| TN                              | 0.046               | 2.63 (1.01-6.83)      | 0.579 | 1.35 (0.46-3.91) |
| Adjuvant chemotherapy (Done vs. Not done) | 0.483            | 1.45 (0.50-4.16)      |

¹Other: primary breast cancer other than IDC or ILC.
3. Risk Stratification Using CART Analysis

CART modeling was performed using statistically significant variables found in the univariate analysis to identify subgroups at higher risk for recurrence. Accordingly, SUVmax >6.75, tumor size >2.0 cm, and molecular subtypes were included in CART analysis. The resulting CART model revealed 4 risk layers based on SUVmax, tumor size, and molecular subtype: group 1 (SUVmax ≤6.75 and tumor size ≤2.0 cm); group 2 (SUVmax ≤6.75, tumor size >2.0 cm, and LumA or TN); group 3 (SUVmax ≤6.75, tumor size >2.0 cm, and LumB or HER2-enriched); group 4 (SUVmax >6.75) (Figure 1). There were 278 (53%) patients in group 1, 52 (10%) in group 2, 33 (6%) in group 3, and 161 (31%) in group 4. LumA was the most common subtype in group 1 and TN was the most common in group 4.

4. Kaplan-Meier Survival Analysis in 4 Risk Layers on CART Modeling

According to the risk layers, the 5-year RFS was 95.9% in group 1, 98% in group 2, 82.8% in group 3, and 85.4% in group 4 (Figure 1). Groups 3 or 4 demonstrate worse prognosis than groups 1 or 2 (group 1 vs. group 3: p=0.040 after adjustment; group 1 vs. group 4: p<0.001 after adjustment; group 2 vs. group 3: p=0.016 after adjustment; group 2 vs. group 4: p<0.001 after adjustment). No significant difference in RFS was observed between patients in group 1 and those in group 2 (p=0.553 after adjustment). The patients in group 3 showed no remarkable difference in RFS compared with those in group 4 (p=0.847 after adjustment).
Fig 1. Classification and regression tree analyses to identify synergistic/antagonistic associations between prognostic factors. Square boxes indicate, respectively, intermediate and terminal subsets of patients defined by the sequential splitting process. There are 4 terminal risk groups. The numbers after molecular subtype are the number of recurrences of the total number of patient in each subtype. Cox proportional hazard model calculated HRs of each groups. * = statistically significant difference for pairwise comparison using log rank test. HER2 = human epidermal growth factor receptor 2; LumA = Luminal A; LumB = Luminal B; TN = triple negative.
IV. DISCUSSION

Because the majority of patients with breast cancer present at an early stage of disease, we included only a large population of stage I and II breast cancer patients who underwent upfront surgery without neoadjuvant chemotherapy.\(^2\)\(^3\) High SUVmax (> 6.75) in the primary tumor was the only independent prognostic factor for RFS in multivariate analysis. Other than SUVmax, tumor size and molecular subtype were significant in univariate analysis. In general, nodal status seems to be the most powerful prognostic factor for RFS in early stage breast cancer.\(^17\)\(^18\) Regardless, it was not prognostic for RFS in this study. There were 125/524 (23.9%) patients with N1 metastasis, in which only a small number (n=23/524 [4.4%]) had N1 metastasis confirmed before surgery. The remaining 102/524 (19.5%) patients had N1 disease according to sentinel lymph node sampling. Most N1 metastasis was not clinically detectable, and improved surgical removal of metastatic lymph nodes and effective adjuvant therapy may have contributed to the result.

SUVmax at staging has been prognostic for RFS in patients with operable breast cancer.\(^19\)\(^-\)\(^25\) However, no studies have evaluated the interactions between clinicopathological and metabolic prognostic factors for risk stratification. We used CART analysis to evaluate high-order associations among the significant factors in univariate analysis for further risk stratification. SUVmax >6.75, tumor size >2.0 cm, and molecular subtypes were included in the analysis, resulting in 4 different risk layers. Among the 4 risk groups based on CART modeling, patients in groups 3 and 4 showed no significant difference in 5-year RFS rates (82.8% and 85.4%, respectively). Patients in groups 1 and 2 also showed no difference in 5-year RFS rates (95.9% and 98%, respectively). The 5-year RFS rates in groups 3 or 4 were significantly worse than those in groups 1 or 2.

As expected in multivariate analysis, high SUVmax was the highest-order risk factor for RFS on CART modeling. In group 4 (SUVmax >6.75), neither size nor molecular subtype was significant for further risk classification. This group
demonstrated a higher HR (7.29) for RFS. In the remaining patients (groups 1, 2, and 3) with low SUVmax (≤6.75), tumor size was the next classification factor. Patients with a tumor size ≤2 cm represented a separate risk layer with a lower HR (1.36) for RFS (group 1). In patients with tumor size >2 cm, there were two different risk layers according to molecular subtype. In patients with LumA or TN subtypes (group 2), the HR (1.00) was similar to that of group 1, whereas it was 8.67 in patients with LumB or HER2-enriched subtypes (group 3), similar to that of group 4. Similar to high SUVmax, LumB or HER2-enriched breast cancers >2 cm appeared to be important in predicting worse RFS in patients with low SUVmax.

TN breast cancer is known to demonstrate the worst survival, whereas LumA has the best survival.26 However, there were interesting risk stratification patterns in patients with TN or LumA subtype in this study. Despite the known poor prognosis of the TN subtype, of the 102 patients with TN, 39 (38%) with low SUVmax showed significantly better RFS than the remaining 63 (62%) patients with high SUVmax. In contrast to LumB or HER2-enriched, tumor size was not prognostic in TN when SUVmax was low. Given that TN subtype demonstrates heterogeneous histology as well as gene expressions27, SUVmax appeared to have potential in differentiating patients with different risks for RFS in TN subtype.

In the LumA subtype, there is a high clinical demand for techniques to identify patients who could benefit from toxic adjuvant chemotherapy. Oncotype DX assay (Genomic Health), based on the expression of 21 genes, has been useful in scoring the likelihood of distant metastasis and aiding in treatment decisions 28. In this study, only 23 (10.2%) of the 225 patients with LumA demonstrated high SUVmax and worse RFS. The remaining 202 (89.8%) patients demonstrated low SUV max and better RFS. Similar to the TN subtype, tumor size was not prognostic in LumA when SUVmax was low. Further studies are needed to determine the value of SUVmax to predict RFS and to select patients for adjuvant chemotherapy in LumA breast cancer.

The present study had several limitations, the first of which was its retrospective
design. However, we analyzed a large homogenous population of patients with stage I and II breast cancer with complete pathological results. Second, we excluded patients whose primary tumor diameter was <1 cm to avoid a partial-volume averaging effect on SUVmax measurement, which may have resulted in exaggerated prognostic value of SUVmax on small size tumors.\textsuperscript{29, 30} Even with partial-volume correction, overcorrection can be problematic in tumors with diameters <1.5 times the full-width at half-maximum.\textsuperscript{31} Regardless, performing \textsuperscript{18}F-FDG PET/CT in patients with breast cancer tumors <1 cm is less likely.

V. CONCLUSION

In this study, we proposed a risk stratification model using clinicopathological and metabolic prognostic factors in stage I and II breast cancer patients who underwent surgery without neoadjuvant chemotherapy. High SUVmax (>6.75) in the primary tumor was an independent prognostic factor for poor RFS. In patients with low SUVmax, LumB or HER2-enriched tumor >2 cm was a poor prognostic factor for RFS, similar to high SUVmax.
REFERENCES

1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., . . . Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer, 136*(5), E359-86. doi:10.1002/ijc.29210

2. Bland, K. I., Menck, H. R., Scott-Conner, C. E., Morrow, M., Winchester, D. J., & Winchester, D. P. (1998). The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. *Cancer, 83*(6), 1262-73.

3. Zagouri, F., Liakou, P., Bartsch, R., Peccatori, F. A., Tsigginou, A., Dimitrakakis, C., . . . Azim, H. A., Jr. (2015). Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal. *Breast, 24*(4), 513-23. doi:10.1016/j.breast.2015.02.031

4. Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., . . . Kumar, R. (2017). NCCN Guidelines Insights: Breast Cancer, Version 1.2017. *J Natl Compr Canc Netw, 15*(4), 433-51.

5. Cianfrocca, M., & Goldstein, L. J. (2004). Prognostic and predictive factors in early-stage breast cancer. *Oncologist, 9*(6), 606-16. doi:10.1634/theoncologist.9-6-606

6. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., . . . Botstein, D. (2000). Molecular portraits of human breast tumours. *Nature, 406*(6797), 747-52. doi:10.1038/35021093

7. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., . . . Borresen-Dale, A. L. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A, 98*(19), 10869-74. doi:10.1073/pnas.191367098

8. Cardoso, F., van't Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., . . . Piccart, M. (2016). 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med, 375*(8), 717-29. doi:10.1056/NEJMoa1602253

9. Prat, A., Adamo, B., Cheang, M. C., Anders, C. K., Carey, L. A., & Perou, C. M. (2013). Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. *Oncologist, 18*(2), 123-33. doi:10.1634/theoncologist.2012-0397

10. Nielsen, T. O., Parker, J. S., Leung, S., Voduc, D., Ebbert, M., Vickery, T., . . . Ellis, M. J. (2010). A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer. *Clinical Cancer Research, 16*(21), 5222-32. doi:10.1158/1078-0432.ccr-10-1282
11. Hatt, M., Visvikis, D., Albaraghach, N. M., Tixier, F., Pradier, O., & Cheze-le Rest, C. (2011). Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. *Eur J Nucl Med Mol Imaging, 38*(7), 1191-202. doi:10.1007/s00259-011-1755-7

12. Liu, F. Y., Chao, A., Lai, C. H., Chou, H. H., & Yen, T. C. (2012). Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma. *Gynecol Oncol, 125*(3), 566-71. doi:10.1016/j.ygyno.2012.03.021

13. Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009). From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. *J Nucl Med, 50 Suppl 1*, 122s-50s. doi:10.2967/jnumed.108.057307

14. Edge, S. B., & Compton, C. C. (2010). The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol, 17*(6), 1471-4. doi:10.1245/s10434-010-0985-4

15. Elston, C. W., & Ellis, I. O. (2002). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. *Histopathology, 41*(3a), 151-2, discussion 152-3.

16. Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., . . . Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *Archives of Pathology & Laboratory Medicine, 131*(1), 18-43. doi:10.1043/1543-2165(2007)131[18:asocco]2.0.co;2

17. Nemoto, T., Natarajan, N., Bedwani, R., Vana, J., & Murphy, G. P. (1983). Breast cancer in the medial half. Results of 1978 National Survey of the American College of Surgeons. *Cancer, 51*(8), 1333-8.

18. Saez, R. A., McGuire, W. L., & Clark, G. M. (1989). Prognostic factors in breast cancer. *Semin Surg Oncol, 5*(2), 102-10.

19. Ohara, M., Shigematsu, H., Tsutani, Y., Emi, A., Masumoto, N., Ozaki, S., . . . Okada, M. (2013). Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer. *Breast, 22*(5), 958-63. doi:10.1016/j.breast.2013.05.003

20. Ahn, S. G., Park, J. T., Lee, H. M., Lee, H. W., Jeon, T. J., Han, K., . . . Jeong, J. (2014). Standardized uptake value of (1)(8)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden. *Breast Cancer Res, 16*(6), 502. doi:10.1186/s13058-014-0502-y

21. Inoue, T., Yutani, K., Taguchi, T., Tamaki, Y., Shiba, E., & Noguchi, S. (2004). Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography. *J Cancer Res Clin Oncol, 130*(6), 413-8. doi:10.1007/s00432-004-0840-0
22. Ueda, S., Tsuda, H., Asakawa, H., Shigekawa, T., Fukatsu, K., Kondo, N., . . . Mochizuki, H. (2008). Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. *Jpn J Clin Oncol*, 38(4), 250-8. doi:10.1093/jjco/hyn019

23. Kim, J., Yoo, S. W., Kang, S. R., Cho, S. G., Oh, J. R., Chong, A., . . . Song, H. C. (2012). Prognostic Significance of Metabolic Tumor Volume Measured by (18)F-FDG PET/CT in Operable Primary Breast Cancer. *Nucl Med Mol Imaging*, 46(4), 278-85. doi:10.1007/s13139-012-0161-9

24. O, J. H., Choi, W. H., Han, E. J., Choi, E. K., Chae, B. J., Park, Y. G., & Kim, S. H. (2013). The Prognostic Value of (18)F-FDG PET/CT for Early Recurrence in Operable Breast Cancer: Comparison with TNM Stage. *Nucl Med Mol Imaging*, 47(4), 263-7. doi:10.1007/s13139-013-0232-6

25. Hyun, S. H., Ahn, H. K., Park, Y. H., Im, Y. H., Kil, W. H., Lee, J. E., . . . Choi, J. Y. (2015). Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer. *Radiology*, 275(1), 235-44. doi:10.1148/radiol.14141129

26. Ahn, S. G., Lee, H. M., Lee, S. A., Jeong, J., & Lee, H. D. (2014). Long-term survival analysis of korean breast cancer patients at a single center: improving outcome over time. *Yonsei Med J*, 55(5), 1187-95. doi:10.3349/ymj.2014.55.5.1187

27. Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nat Rev Clin Oncol*, 13(11), 674-90. doi:10.1038/nrclinonc.2016.66

28. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., . . . Wolmark, N. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med*, 351(27), 2817-26. doi:10.1056/NEJMoa041588

29. Avril, N., Menzel, M., Dose, J., Schelling, M., Weber, W., Janicke, F., . . . Schwaiger, M. (2001). Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. *J Nucl Med*, 42(1), 9-16.

30. Srinivas, S. M., Dhurairaj, T., Basu, S., Bural, G., Surti, S., & Alavi, A. (2009). A recovery coefficient method for partial volume correction of PET images. *Annals of Nuclear Medicine*, 23(4), 341-8. doi:10.1007/s12149-009-0241-9

31. Geworski, L., Knoop, B. O., de Cabrejas, M. L., Knapp, W. H., & Munz, D. L. (2000). Recovery correction for quantitation in emission tomography: a
feasibility study. *Eur J Nucl Med*, 27(2), 161-9.
ABSTRACT (IN KOREAN)

조기 유방암 환자의 원발중양 $^{18}$F-fluorodeoxyglucose 섭취와
임상병리적 인자를 활용한 계층적 예후모델 제시

<지도교수 윤�蚰진>

연세대학교 대학원 의학과
차종태

본 연구의 목적은 수술 전 항암 요법을 받지 않은 조기 유방암 환자에서
양전자 컴퓨터 단층 활영 영상의 원발중양 $^{18}$F-fluorodeoxyglucose 섭취
정도가 환자의 재발을 예측하는 예후 인자임을 확인하고 더 나아가
고위험군 환자를 분류하는데 있어 다른 예후 인자들과 어떻게
상호작용하는지 분석하는 것이다.

대상 및 방법: 2008년 1월부터 2013년 12월까지 수술 전 항암 요법을 받지
않은 524 명의 조기 유방암 환자를 모집하였다. 콕스-비례위험모형을 통해
최대 표준화섭취계수 (SUVmax) 및 임상병리적 인자를 중심의 무 재발
생존과 관련된 예후인자들을 찾았다. 그 후 찾은 인자들을 이용하여 분류
및 회귀 트리 모델 분석을 시행하고 재발 위험에 따라 환자를 층계화한
때 예후 인자들끼리 어떻게 상호작용 하는지를 분석한 예후 모델을
제시하였다. 마지막으로 카풀란마이어법 및 로그순위법을 통해 층계화된
그룹들의 생존곡선을 비교하였다.
결과: 추적관찰 기간의 중위값은 46.2 개월이었고, 추적관찰 중 재발한 환자는 총 31명이었다 (국소전이 8명, 원격전이 23명). 일반량 분석에서는 종양의 SUVmax (>6.75), 크기 (>2.0 cm), 그리고 삼중음성 유형이 나쁜 예후 인자였다. 그리고 다변량 분석에서는 SUVmax 만이 독립적인 나쁜 예후 인자였다 (p=0.028). 분류 및 회귀 트리 모델 분석은 재발 위험도에 따라 환자를 네 그룹으로 나누었다(그룹 1 (SUVmax ≤6.75 그리고크기≤2.0 cm); 그룹 2 (SUVmax ≤6.75, 크기>2 cm, 그리고루미날 A 또는삼중음성 유형); 그룹 3 (SUVmax ≤6.75, 종양의 크기 >2.0 cm, 그리고루미날 B 혹은상피성장인자 수용체 과발현 유형); 그룹 4 (SUVmax >6.75)). 각 그룹의 무재발 5년 생존율은 다음과 같았다: 95.9% (그룹 1), 98% (그룹 2), 82.8% (그룹 3), and 85.4% (그룹 4). 그룹 3 과 그룹 4 는 그룹 1 과 그룹 2 보다 나쁜 예후를 보였다.

결론: 조기 유방암 환자에서 원발 종양의 높은 SUVmax 값을 독립적인 나쁜 예후 인자였다. SUVmax 값이 낮더라도 종양의 크기가 2 cm 이상인 루미날 B 혹은 상피성장인자 수용체 과발현 유형은 SUVmax 값이 높은 그룹만큼이나 안 좋은 예후를 보였다.